• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by GreenLight Biosciences Holdings PBC

    7/24/23 10:50:58 AM ET
    $GRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRNA alert in real time by email
    POS AM 1 d504520dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on July 24, 2023

    Registration No. 333-262574

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 4

    TO

    FORM S-1

    ON

    FORM S-3

    REGISTRATION STATEMENT NO. 333-262574

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    GreenLight Biosciences Holdings, PBC

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   85-1914700

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    29 Hartwell Ave

    Lexington, Massachusetts 02421

    (617) 616-8188

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Dr. Andrey J. Zarur

    President and Chief Executive Officer

    29 Hartwell Avenue

    Lexington, Massachusetts 02421

    (617) 616-8188

    (Name, address, including ip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Nate Gallon

    Noah Kornblith

    O’Melveny & Myers LLP

    2765 Sand Hill Rd

    Menlo Park, California 94025

    (650) 473-2604

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF UNSOLD SECURITIES

    This Post-Effective Amendment No. 4 filed by GreenLight Biosciences Holdings, PBC, a Delaware corporation (the “Registrant”), deregisters any and all securities remaining unissued under the following Registration Statement on Form S-1, as subsequently amended by several Post-Effective Amendments on Form S-1 and on Form S-3 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”):

     

      •  

    Registration Statement No. 333-262574, initially filed with the Commission on February 7, 2022 and declared effective on February 14, 2022.

    Pursuant to the Agreement and Plan of Merger, dated as of May 29, 2023 (the “Merger Agreement”), by and between the Registrant, SW ParentCo, Inc., a Delaware corporation (“Parent”), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant surviving the Merger as a wholly-owned subsidiary of Parent. The Merger became effective on July 24, 2023, upon the filing of the certificate of merger with the Secretary of State of the State of Delaware.

    As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement and, in accordance with the undertaking made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities registered thereunder which remain unsold at the termination of the offering, hereby removes and withdraws from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 4 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on this July 24, 2023. No other person is required to sign this Post-Effective Amendment No. 4 to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    GREENLIGHT BIOSCIENCES HOLDINGS, PBC
    By:   /s/ Andrey J. Zarur
    Name: Andrey J. Zarur
    Title: President and Chief Executive Officer
    Get the next $GRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRNA

    DatePrice TargetRatingAnalyst
    12/8/2022$4.00Buy
    Canaccord Genuity
    10/14/2022$5.50Outperform
    Credit Suisse
    More analyst ratings

    $GRNA
    Financials

    Live finance-specific insights

    See more
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC

      15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      8/11/23 9:00:27 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)

      8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/28/23 9:02:32 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by GreenLight Biosciences Holdings PBC

      EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/26/23 12:15:07 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kodiak Venture Partners Iii Lp

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:55:29 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:48:26 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Clarke Dennis A.

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:25:48 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GreenLight Announces Completion of Merger with Fall Line Endurance Fund

      LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r

      7/24/23 9:49:15 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

      6/3/23 8:17:00 PM ET
      $AAIC
      $EMBK
      $GRNA
      $REUN
      Real Estate Investment Trusts
      Real Estate
      Computer Software: Prepackaged Software
      Technology

    $GRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 4:25:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 10:54:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/27/23 4:24:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GreenLight Biosciences with a new price target

      Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00

      12/8/22 9:11:51 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse initiated coverage on GreenLight Biosciences with a new price target

      Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

      10/14/22 7:27:11 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care